Anavex Life Sciences Corp (AVXL)

[falconer66a]

Very definitive. Blarcamesine is safe, and works.

Woke up this morning, turned on my desktop computer to see what appeared this morning. Saw that Anavex has put up a new presentation. Clicked on it, and, wow. Pages of data (didn’t see a single datum from a mouse or rat).

I wanted to check the following:

A) Solid evidence of efficacies against listed, targeted CNS diseases — lots of it.

B) Are the efficacy data points statistically significant (p = <0.05) — p-values all very low; profound statistical significance; results not by chance or placebo effects.

C) What diseases and conditions are being targeted — nothing new there; just a broad range of giant CNS diseases, of expansive, global importance and occurrence.

D) What are the side effects of blarcamesine in any and all of the presented studies — virtually none; unique for a drug acting in the CNS.

Of course, most common retail equity investors couldn’t (or wouldn’t) parse out the confirming data. They are still in the dark about Anavex. They will wait to read of FDA approval in the New York Times. I’m not expecting any stout AVXL share price rise today.

Others? Well, anyone with even a low undergraduate level of biological knowledge should be impressed. The data speak for themselves. Blarcamesine is safe, is administered orally in low doses, and in a variety of CNS diseases facilitates, promotes, and causes very significant therapeutic improvements. The molecule works; like no other.

As always, contrary views of the presentation are warmly invited. Please tell, how does this fail to tell the Anavex story?